Summary
Antidepressant drugs in common use are reviewed in terms of their risks and benefits. A simple classification divides these into tricyclic antidepressants, monoamine oxidase inhibitors and second generation antidepressants.
Risks may arise from the correct use of an antidepressant, from its incorrect or inappropriate use, or due to its failure to reverse the depression. The greatest risk is to leave the depression untreated. Risks due to adverse drug effects are generally predictable but in some cases are unexpected and have led to the withdrawal of the drug from the market.
Assessing the benefits of antidepressant drugs is more difficult. Rating scales can be used in this context and the fact that the majority of antidepressant drugs have a similar degree of efficacy serves to emphasise the importance of making a risk-benefit assessment of each drug. This has been presented for the more widely used drugs. Safety in overdose is a particularly important benefit.
The ideal antidepressant should specifically reverse depressive illness without toxic effects. Although no drug at present measures up to this it is clear that antidepressants should be prescribed, as their benefits outweigh their risks.
Similar content being viewed by others
References
Arnoff GM. Trazodone associated with priapism. Lancet 1: 856, 1984
Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Archives of General Psychiatry 33: 1029, 1976
Baldwin RC, Jolley DJ. The prognosis of depression in old age. British Journal of Psychiatry 149: 574–583, 1986
Barnes TRE, Greenwood DT. Viloxazine and migraine. Lancet 2: 1368, 1979
Barraclough BM, Bunch J, Nelson B, Sainsbury P. 100 cases of suicide: clinical aspects. British Journal of Psychiatry 125: 355–373, 1974
Blackwell B. Antidepressant drugs. In Dukes MNG (Ed.) Meyler’s side effects of drugs, 10th ed., pp. 25–61, Elsevier Science Publishers BV, 1984
Blackwell B. Antidepressant drugs. In Dukes MNG (Ed.) Side effects of drugs, Annual 9, pp. 19–26, Elsevier Science Publishers BV, 1985
Burgess CD, Montgomery S, Wadsworth J, Turner P. Cardiovascular effects of mianserin, zimeldine, nomifensine, in depressed patients. Postgraduate Medical Journal 55: 704–708, 1979
Burrows GD, Vohra J, Hunt D, et al. Cardiac effects of different tricyclic antidepressant drugs. British Journal of Psychiatry 129: 335–341, 1976
Cassidy SL, Henry JA. Fatal toxicity of antidepressant drugs in overdose. British Medical Journal, in press, 1987
Charney DS, Heninger GR, Sternberg DE, Landis H. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. British Journal of Psychiatry 141: 377–386, 1982
Coccaro EF, Siever LJ. Second generation antidepressants: a comparative review. Journal of Clinical Pharmacology 25: 241–260, 1985
Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in treatment of depression of women with cancer. Acta Psychiatrica Scandinavica 72 (Suppl. 320): 85–92, 1985
Coull DC, Crooks J, Dingwall-Fordyce I, Scott AM, Weir RD. Amitriptyline and cardiac disease: risks of sudden death identified by monitoring system. Lancet 2: 590–591, 1970
Craft AW. Circumstances surrounding deaths from accidental poisoning, 1974–1980. Archives of Disease in Childhood 58: 544–546, 1983
Crome P. Poisoning due to tricyclic antidepressant overdosage: clinical presentation and treatment. Medical Toxicology 1: 261–285, 1986
Crome P, Ali P. Clinical features and management of self-poisoning with newer antidepressants. Medical Toxicology 1: 411–420, 1986
Crome P, Newman B. Poisoning with maprotiline and mianserin. British Medical Journal 2: 260, 1977
Croog SH, Levine S, Testa MA, Brown B. The effects of anti-hypertensive therapy on the quality of life. New England Journal of Medicine 314: 1657–1664, 1986
CSM Update. Adverse reactions to antidepressants. British Medical Journal 291: 1638, 1985
CSM Update. Withdrawal of nomifensine. British Medical Journal 293: 41, 1986
Data Sheet 1986. Revised data sheet issued by Organon Laboratories in agreement with Committee on Safety of Medicines — May 1986
Davies RK, Tucker DJ, Harrow M, Detre TP. Confusional episodes and antidepressant medication. American Journal of Psychiatry 128: 127, 1971
Editorial. Product News — Welbutrin launch delayed. Scrip No. 1083 (March 10): 20, 1986
Editorial. La courageuse décision de Pharmuka. Gazette Medicale 92: 27, 1985
Evans DL, Davidson J, Raft D. Early and late side effects of phenelzine. Journal of Clinical Psychopharmacology 2: 208–210, 1982
Feldmann HS, Denber HCB. Long-term study of fluvoxamine: a new rapid-acting antidepressant. International Pharmacopsychiatry 17: 114–122, 1982
Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs v TCAs in treating depression in the elderly. Biological Psychiatry 21: 1155–1166, 1986
Gerner RH. Present status of drug therapy of depression in late life. Journal of Affective Disorders (Suppl. 1): S23-S31, 1985
Gerner R, Eastbrook W, Steuer J, Jarvik L. Treatment of geriatric depression with trazodone, imipramine and placebo: a double-blind study. Journal of Clinical Psychiatry 41: 216–220, 1980
Goldberg D. Identifying psychiatric illness among general medical patients. British Medical Journal 291: 161–162, 1985
Griffin N, Draper RJ, Webb MGT. Addiction to tranylcypromine. British Medical Journal 283: 346, 1981
Gruter W, Poldinger W. Maprotiline. Modern Problems in Pharmacopsychiatry 18: 17–48, 1982
Guy W(Ed.). CGI Clinical Global Impressions. ECDEU assessment manual for psychopharmacology (DHEW Publication no. 76338), pp. 218–222, Department of Health, Education and Welfare, Washington, D.C., 1976
Guze SB, Robins E. Suicide among primary affective disorders. British Journal of Psychiatry 117: 437–438, 1970
Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 32: 50–55, 1959
Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23: 46–62, 1960
Hamilton M. Comparative value of rating scales. British Journal of Clinical Pharmacology 3 (Suppl.): 58–60, 1976
Himmelhoch JM, Schechtman K, Auchenback R. The role of trazodone in the treatment of depressed cardiac patients. Psychopathology 17 (Suppl. 2): 51–63, 1984
Hollister LE. Current antidepressant drugs: their clinical use. Drugs 22: 129–152, 1981
Jabbari B, Bryan G, Mars LEE, Gunderson CH. Incidence of seizure with tricyclic and tetracyclic antidepressants. Archives of Neurology 42: 480–481, 1985
Janowsky D, Curtis G, Zisook S, et al. Ventricular arrhythmias possibly aggravated by trazodone. American Journal of Psychiatry 140: 796–797, 1983
Knudsen K, Heath A. Effects of self poisoning with maprotiline. British Medical Journal 288: 601–603, 1984
Kronig MH, Roose SP, Walsh BT, et al. Blood pressure effects of phenelzine. Journal of Clinical Psychopharmacology 3: 307–308, 1983
Lewis JA. Postmarketing surveillance: how many patients? Trends in Pharmacological Sciences 2: 93–94, 1981
Litovitz TL, Troutman WG. Amoxapine overdose: seizures and fatalities. Journal of the American Medical Association 250: 1069–1071, 1983
Mendez MF, Cummings JL, Benson DF. Psychotropic drugs and epilepsy. Stress Medicine 2: 325–332, 1986
Moir DC, Crooks J, Cornwell WB, et al. Cardiotoxicity of amitriptyline. Lancet 2: 561–564, 1972
Moir DC, Dingwall-Fordyce I, Weir RD. Medicines evaluation and monitoring group: a follow-up study of cardiac patients receiving amitriptyline. European Journal of Clinical Pharmacology 6: 98–101, 1973
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134: 382–389, 1979
Morris JB, Beck AT. The efficacy of antidepressant drugs: a review of research (1958-1972). Archives of General Psychiatry 30: 667, 1974
Murphy E. General management of depression in late life. Journal of Affective Disorders (Suppl. 1): S7-S10, 1985
Nilsson BS. Adverse reactions in connection with zimeldine treatment: a review. Acta Psychiatrica Scandinavica 308 (Suppl. 1): 115–119, 1983
Ofsti E. Citalopram — a specific 5-HT reuptake inhibitor — as an antidepressant drug: a phase II multicentre trial. Progressive Neuro-Psychopharmacology and Biological Psychiatry 6: 327–335, 1982
O’Sullivan K. Depression and its treatment in alcoholics: a review. Canadian Journal of Psychiatry 29: 379–384, 1984
Overall JE. Efficacy of nomifensine in different depressive syndromes. Journal of Clinical Psychiatry 45 (4 Sec. 2): 85–88, 1984
Paykel ES, Mueller PS, De La Vesgne PM. Amitriptyline, weight gain and carbohydrate craving: a side-effect. British Journal of Psychiatry 123: 501–507, 1973
Peabody CA, Whiteford HA, Hollister LE. Antidepressants and the elderly. Journal of the American Geriatrics Society 34: 869–874, 1986
Pentel PR, Benowitz NL. Tricyclic antidepressant poisoning: management of arrhythmias. Medical Toxicology 1: 101–121, 1986
Prescott LF, Highley MS. Drugs prescribed for self poisoners. British Medical Journal 290: 1633–1636, 1985
Pugh R, Bell J, Cooper AJ, Dunstan S, Greedharry D, et al. Does lofepramine have fewer side effects than amitriptyline: results of a comparative trial. Journal of Affective Disorders 4: 355–363, 1982
Rabkin JG, Quitkin FM, McGrath P, et al. Adverse reactions to monoamine oxidase inhibitors, part II: treatment correlates and clinical management. Journal of Clinical Psychopharmacology 5: 1–9, 1985
Rickels K, Weise CC, Csanalosi I, et al. Clomipiamine and amitriptyline in depressed outpatients: a controlled study. Psychopharmacologia 34: 361–376, 1974
Roos JC. Cardiac effects of antidepressant drugs: a comparison of the tricyclic antidepressants and fluvoxamine. British Journal of Clinical Pharmacology 15: 439S–445S, 1983
Scher M, Krieger JN, Juergens S. Trazodone and priapism. American Journal of Psychiatry 140: 1362–1363, 1983
Skegg K, Skegg DCG, Richards SM. Incidence of self poisoning in patients prescribed psychotropic drugs. British Medical Journal 286: 841–848, 1983
Snaith RP, Taylor CM. Rating scales for depression and anxiety: a current perspective. British Journal of Clinical Pharmacology 19: 17S–20S, 1985
Tyrer P. Drug treatment of psychiatric patients in general practice. British Medical Journal 2: 1008–1010, 1978
Veith RC, Raskind M, Caldwell JH, et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. New England Journal of Medicine 306: 954–959, 1982
Vlay SC, Friedling S. Trazodone exacerbation of VT. American Heart Journal 106: 604, 1983
Waite J, Grundy E, Arie T. A controlled trial of antidepressant medication in elderly in-patients. International Clinical Psychopharmacology 1: 113–126, 1986
Wedin GP, Oderda G, Klein-Schwartz W, Gorman R. Relative toxicity of cyclic antidepressants. Annals of Emergency Medicine 14: 797–804, 1986
Zung W, Magill M, Moore J, George D. Recognition and treatment of depression in family practice. Journal of Clinical Psychiatry 44: 3–6, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Henry, J.A., Martin, A.J. The Risk-Benefit Assessment of Antidepressant Drugs. Med Toxicol Adverse Drug Exp 2, 445–462 (1987). https://doi.org/10.1007/BF03259878
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259878